Pulmonx Corporation Q2 FY2026 earnings call

• Business Geographic Distribution: Approximately two thirds of the company's total business is generated in the United States, while one third comes from international operations. 90% of the company's international business originates from European markets, with the largest markets being Germany, the UK, France, followed by Spain, Benelux, Italy, and Switzerland.
• Clinical Program Status: The CONVERT II trial is a global clinical trial that includes sites in the United States, multiple European markets, and Australia. The publication of results from the ConvertOne trial has been submitted for formal peer review publication.
• Strategic Priorities: Management's core current priorities are strengthening the company's sales organization, advancing all ongoing clinical programs, and improving the company's financial leverage. Management expresses confidence in its team and the current business trajectory to deliver improved business outcomes for patients with severe emphysema.

No financial performance data for product segments or overall revenue is provided in the excerpted transcript.

No formal full-year or medium-term financial or operational guidance is provided in the excerpted transcript. Management only confirms that with existing cash on hand and access to the established milestone-based debt facility, the company has a clear path to reach cash flow break-even within the next few years.

No explicit discussion of business risks, operational failures, or downside challenges is included in the excerpted transcript.

Q: When will AeroSeal launch in CE-marked European nations, and will country-by-country commercialization be allowed after local enrollment completion for CONVERT II?

A: AeroSeal already holds CE marking, so it does not require the same full regulatory approval pathway needed for the US market, and it will launch in Europe sooner than in the US. Key rate-limiting steps are publication of ConvertOne results and completion of CONVERT II patient enrollment in European OUS markets; after enrollment concludes, a 90-180 day period of training and standard launch activities is required before commercial sales begin. The company does not set country-specific enrollment targets, and will pursue commercialization after overall OUS enrollment is complete, rather than launching in individual countries as local enrollment finishes.

Q: What is the company's current path to cash flow break-even given existing cash and the new milestone-based debt facility?

A: Management confirms it is confident in the path to cash flow break-even. The combination of current cash on hand and the additional capital buffer from the accessible debt facility provides sufficient funding to reach break-even over the next few years.